Precision Biosciences (DTIL) EBT Margin (2018 - 2026)
Precision Biosciences (DTIL) reported EBT Margin of 77.39% for Q1 2026, up 7282951.0% year-over-year from N/an in Q1 2025, and down 304.66% quarter-over-quarter from 37.81% in Q4 2025.
Precision Biosciences (DTIL) EBT Margin (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of EBT Margin data on file, last reported at 77.39% in Q1 2026.
- EBT Margin for Q1 2026 came in at 77.39%, up 7282951.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 81.15% (down 444.0% YoY), and the FY2025 annual result was 143.97%, down 11314.0% from the prior year.
- EBT Margin eased to 77.39% in Q1 2026 per DTIL's latest filing, from 37.81% in the prior quarter.
- Over five years, EBT Margin peaked at 50.96% in Q2 2024 and troughed at 153861.54% in Q3 2025.
- A 5-year average of 20797.69% and a median of 188.9% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2025 and 2026: EBT Margin plunged 15042959 bps in 2025, then soared 7282951 bps in 2026.
- A 5-year view of EBT Margin shows it stood at 100.57% in 2022, then slumped by 93 bps to 193.83% in 2023, then sank by 1820 bps to 3721.63% in 2024, then jumped by 101 bps to 37.81% in 2025, then sank by 305 bps to 77.39% in 2026.
- Business Quant data shows DTIL's EBT Margin at 77.39% in Q1 2026, 37.81% in Q4 2025, and 153861.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - | -77.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.39% |
| Dec 31, 2025 | 37.81% |
| Sep 30, 2025 | -153,861.54% |
| Jun 30, 2025 | -117,327.78% |
| Mar 31, 2025 | -72,906.90% |
| Dec 31, 2024 | -3,721.63% |
| Sep 30, 2024 | -3,431.94% |
| Jun 30, 2024 | 50.96% |
| Mar 31, 2024 | -17.62% |
| Dec 31, 2023 | -193.83% |
| Sep 30, 2023 | -84.37% |
| Jun 30, 2023 | -8.77% |
| Mar 31, 2023 | -134.77% |
| Dec 31, 2022 | -100.57% |
| Sep 30, 2022 | -188.90% |
| Jun 30, 2022 | -773.30% |
| Mar 31, 2022 | -820.17% |
| Dec 31, 2021 | -484.52% |
| Sep 30, 2021 | -48.07% |
| Jun 30, 2021 | 31.47% |